|
OMNICOMM DELIVERS ITS STUDY DATA TABULATION MODEL (SDTM) EXPORT TOOL AHEAD OF ITS PLANNED 2010 RELEASE DATE.
Fort Lauderdale, FL, October 16, 2009 - /Marketwire/ OmniComm Systems,
Inc. (OTC: OMCM.OB), one of the fastest growing companies in the electronic
data capture (EDC) marketplace, announced today that its new SDTM solution is ready,
ahead of schedule, and is available to its customers for deployment and implementation
into clinical studies. This new solution was developed for OmniComm’s flagship EDC
product, TrialMaster™ and will allow for mapping and exporting of data directly
into the CDISC SDTM format, ensuring an accelerated pathway towards electronic submission
of clinical data. OmniComm is a CDISC ODM certified and is known in the industry
for its commitment to standards and for bringing innovative eClinical solution to
the life science industry. OmniComm’s TrialMaster solution has supported the CDISC
ODM, CDASH (including naming conventions and domain structures), HL7, E2B, and caBIG
standards for years, and with the addition of CDISC SDTM, will be the first EDC
company to leverage all of the industry leading standards in a single solution.
"TrialMasterTM offers an end-to-end solution from designing electronic case report
forms (eCRFs) that support the CDASH naming conventions, to supporting the export
of the CDISC submission format (SDTM), the preferred method for submission by the
Food and Drug Administration," commented Stephen Johnson, OmniComm’s COO."Our focus
is on how to aggregate, extract and export the data into industry standards while
reducing the time between database lock and reporting to FDA. OmniComm has always
been on the forefront of adopting new technologies. For example, we are currently
working with one of our customers at a premier research institute to integrate our
TrialMaster application with their Electronic Health Records (EHR) system to integrate
healthcare and clinical research data. We are constantly searching for better ways
to improve clinical research through the use of innovative technologies."
About OmniComm
OmniComm Systems, Inc. (www.OmniComm.com)
provides customer-driven Internet solutions to pharmaceutical, biotechnology, research
and medical device organizations that conduct life changing clinical trial research.
OmniComm's growing base of satisfied customers is a direct result of the company's
commitment to deliver products and services that ensure ease of use, faster study
build, ease of integration and better performance. OmniComm's client intuitive pricing
model allows companies that range from small, to mid-size to large scale institutions
to safely and efficiently capitalize on their clinical research investments. OmniComm
Systems, Inc has U.S. headquarters in Fort Lauderdale, FL and European headquarters
in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and
Russia as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Safe Harbor Disclaimer Statements made by OmniComm included in this release may
constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties
such as the Company's ability to obtain new contracts and accurately estimate net
revenues due to uncertain regulatory guidance, variability in size, scope and duration
of projects, and internal issues at the sponsoring client, integration of acquisitions,
competitive factors, technological development, and market demand. As a result,
actual results may differ materially from any financial outlooks stated herein.
Further information on potential factors that could affect the Company's financial
results can be found in the Company's Reports on Form 10-K and 10-Q filed with the
Securities and Exchange Commission. The Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information, future
events, or otherwise.
CONTACT: Stephen Johnson at: + 1 954-377-1726
Back
|
